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ABSTRACT
Embryonic stem cells (ESCs), due to their ability to differentiate into different
cell types while still maintaining a high proliferation capacity, have been considered as a
potential cell source in regenerative medicine. However, current ESC differentiation
methods are low yielding and create heterogeneous cell populations. If transplanted in the
human body, differentiated ESCs could be rejected by the immune system, form tumors,
or may not function normally within the human body. On the other hand, mesenchymal
stem cells (MSCs), a type of adult stem cell typically derived from bone marrow, have
proved to be excellent candidates in clinical applications due to their defined
differentiation capacity and immunoregulatory properties. However, MSCs lack
sufficient expansion capacity and can only be derived from limited tissues. This project
entails characterizing ESCs differentiated through retinoic acid induction as MSCs. It is
speculated that these cells are MSCs due to the extensive similarities in behavior and
differentiation capacity. To complete the characterization, the morphology of our MSCs
was compared to naturally differentiated MSCs, and a cell cycle analysis was performed.
The tentative MSCs were spontaneously differentiated into osteocytes, adipocytes, and
chondrocytes, the three distinct cell lineages that characterize MSCs differentiation
capacity. Based on the results, our cells were determined to be MSCs, thereby identifying
them as ESC-MSCs. This is significant, because it allows for the formation of cells that
bypass many of the challenges mentioned above. ESC-MSCs express combined
advantages from both ESCs and MSCs, making them even better cell sources for future
therapeutic applications.
Key Words: mESCs, transcription factors, MSCs, differentiation, regenerative medicine
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INTRODUCTION
Stem cells are characterized as cells that have the ability to continuously
proliferate (self-renewal), while also maintaining the capacity to differentiate into
different cell lineages (potency). The self-renewal capacity and potency properties of
stem cells are what make them different from ordinary somatic cells and exciting tools
for cell research. There are two main categories of stem cells including embryonic stem
cells (ESC) and adult stem cells (ASC).
Embryonic Stem Cells
Background
About twenty-five years ago, the discovery of ESCs sparked an impressive
advancement in cellular biology and medicine (Keller, 2005). Research on ESCs began
when the very first stem cells, the embryonic carcinoma (EC) cells, were established in
the early 1970s. EC cells were first formed as cell lines from germ line tumors known as
teratocarcinomas. Isolated EC cells displayed differentiation abilities and were able to
transform into the derivatives of the three primary germ layers: endoderm, mesoderm,
and ectoderm. Furthermore, EC cells were found to participate in embryonic
development when the cells were transferred to the inner cell mass (ICM) of early
chimeric mice embryos. However, after this process occurred, the EC cells lost their
pluripotent capabilities and were no longer able to differentiate into specialized cells.
Many of these cells also showed chromosomal abnormalities. This setback sparked the
search for an alternate stem cell line. It was this investigation that led to the development
of ESCs.
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In hopes of avoiding the chromosomal alterations associated with teratocarcinoma
growth, mouse ESCs (mESC) were isolated in 1981. Using different techniques, two
scientists, Evan and Kaufman, were able to successfully cultivate cell lines from mouse
blastocysts that preserved the cells differentiation abilities (Wobus & Boheler, 2005). In
1998, Thompson, et al. were able to derive human ESC (hESC) cell lines from
blastocysts that were generated from in vitro fertilized human eggs.
A fertilized egg, the first entity of life, has totipotent capabilities, meaning it is
able to produce an entire organism. Totipotency persists in the zygote until about the
eight-cell stage, which is also known as the morula. About three to four days after
fertilization takes place, a blastocyst is formed through cell differentiation. The blastocyst
is composed of outer trophoblast cells, a trophectoderm layer that provides nutrients to
the embryo, which further develops into the placenta, and inner undifferentiated cells,
which composes the ICM. The cells of the ICM will form all other tissues and organs.
They are pluripotent, which is defined as the capacity for a cell to develop into any type
of cell given the proper conditions. It is at the stage of the ICM where ESCs are derived
as shown in Figure 1 (Wobus & Boheler, 2005).
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Figure 1: Isolation and Culture of ESCs. After fertilization, the blastocyst forms
including both the trophectoderm layer and the ICM. The ICM is harvested five to seven
days after fertilization and embryonic stem cells are cultured (Landry & Zucker, 2004).

The pluripotency of ESCs were demonstrated when they were able to differentiate
into all three primary germ layers after implantation into a host blastocyst (Keller, 2005).
The primary germ layers include the endoderm, mesoderm, and ectoderm. The cells of
the endoderm give rise to the epithelial lining of major body systems including
respiratory, gastrointestinal, and urinary. The mesoderm forms connective tissue,
cartilage, and bone, and also gives rise to important organs including the kidneys,
ovaries, and spleen. Whereas the ectoderm forms the central and peripheral central
nervous systems, epidermis, mammary glands, and sensory tissue of the eye, ear, and
nose. Together, the three germ layers are able to form every organ in the body (Panski,
1982). When a pluripotent cell becomes a tissue cell of one of the germ layers, it then
becomes multipotent. This means it has limited differentiation potential and is restricted
to differentiating into cells of specific tissue types. For example, the cells of the inner
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germ layer or endoderm are only capable of becoming cells such as pancreas or liver
cells. The middle or mesoderm layer cells can only differentiate into cell types such as
muscle, bone, or cartilage. The outer germ layer or ectoderm cells are only capable of
becoming cell types including epithelial and nerve cells (Wobus & Boheler, 2005). An
example of ESC’s differentiation potential is shown in Figure 2.
ESC

Figure 2: The differentiation potential of ESCs. ESCs can differentiate into different cell
types that can be used for different purposes including structural (cartilage and bone
cells) and signaling (beta cells.) These cells then become specialized with their own
specific functions. (Wu & Belmonte, 2014)

Characteristics
One of the hallmark features of ESCs in culture is their ability to remain in the
pluripotent state while dividing indefinitely. In vitro, the cells can remain in this state for
several years if cultured under the appropriate conditions, but at the molecular level, the
maintenance of this undifferentiated state is more complex. It is maintained by several
transcription factors working together to promote proliferation and prevent differentiation
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(Niwa, 2007). The three main transcription factors involved in this process are Oct4,
Nanog, and Sox2. They work by activating target genes that encode self-renewal and
pluripotency and repressing the signaling pathways involved in promoting differentiation.
There are more than three hundred genes that are simultaneously being either expressed
or repressed by these three transcription factors alone (Chan, Yang and Ng, 2011).
The unique cell cycle of ESCs is yet another factor contributing to their stem cell
state. Somatic cell cycles involve four discrete stages that conclude in the formation of
two daughter cells each with identical contents. During the synthesis phase or S phase of
the cell cycle, the genetic information is replicated. The actual physical division of the
two cells occurs during the mitotic phase or M phase. Between these two phases exists
the gap phases (G 1 and G 2 ), where cell growth and preparation for division occurs. The
notable differences in ESC’s cell cycle include much shorter gap phases and a longer S
phase. In all pluripotent cells, about 60% of the cells are in the S phase, but as ESCs
begin to differentiate, their cell cycles become more like that of somatic cells (White &
Dalton, 2005).
In Vitro Maintenance of Pluripotency
The cultivation of ESCs begins five to seven days after fertilization when the ICM is
isolated from the blastocyst. The ICM is then cultured in a specific medium to maintain
their pluripotent nature (Wobus & Boheler, 2005). Initially, cultivation required ESCs be
grown in a culture medium containing both bovine serum and mouse embryonic
fibroblasts, a type of feeder cell thought necessary for ESC undifferentiated state (Amit et
al., 2006). However, recently it was found that the leukemia inhibitory factor (LIF), and
not the feeder cell layer, was responsible for promoting mESC proliferation and
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suppressing differentiation in vitro. A part of the interleukin-6 family of cytokines, LIF is
a soluble glycoprotein that activates Stat3, promoting the undifferentiated state in
mESCs, but not in hESCs (Wobus & Boheler, 2005). It has been noted that the activation
of Stat3 is not sufficient to maintain the stem cell state of hESC. This suggests that there
is a fundamental difference between the human and murine mechanisms for maintaining
pluripotency (Humphrey et al., 2004).
In Vitro Differentiation of ESCs
Various methods have been established to differentiate ESCs in vitro.
Spontaneous differentiation of ESCs is among the most commonly used. When the
factors maintaining their stem cell state, such as LIF, are removed, ESCs will
spontaneously differentiate into various cell types. By allowing ESCs to spontaneously
differentiate in culture, several cell types have been formed including cells from each of
the three germ layers, endoderm, mesoderm, and ectoderm (Keller, 2005). Another
common ESC differentiation method includes the use of growth factors or cytokines to
induce differentiation into specific cell lineages. For example, in order for ESCs to
differentiate into endothelial cells, vascular endothelial growth factor and basic fibroblast
growth factor are typically used. Though these differentiation methods are capable of
forming several different cell lineages, both lead to low-yielding and heterogeneous cell
populations that cannot be used for medical application. Due to these deficiencies, other
methods of differentiation are being researched.
In 2006, Takahashi and Yamanaka discovered induced pluripotent stem cells
(iPSCs). They were able to successfully reprogram mouse somatic cells into pluripotent
cells using key transcription factors (Puri & Nagy, 2012). This was an extraordinary
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breakthrough in stem cell research, and it is from this discovery that we now know that
somatic cells have the potential to be reprogramed to pluripotency. This brought upon
this new idea of cell reprogramming, and how specific transcription factors can be used
to induce differentiation. This method is believed to be able to differentiate unlimited cell
lineages from iPSCs generated from a patient (Daubman, 2011).
These transcription factors have already been identified for a number of cell
lineages, including the factors directing differentiation into bone, fat, and cartilage.
Transcription factor Runt-related transcription factor 2 (RUNX2) has been named the
essential transcription factor for osteogenic differentiation, bone matrix gene expression,
and bone mineralization (Nakahara et al., 2010). During adipogenesis, there are a few
different transcription factors that play a major role while directing differentiation.
Peroxisome Proliferator-activated receptor γ (PPARγ) has been identified as the master
regulator for adipocyte formation. Without its expression, precursor cells cannot
differentiate into an adipocyte phenotype. Also members of the CCAAT/enhancerbinding protein (C/EBP) family of transcription factors have also been found to play a
role in the late stages of adipogenic differentiation (Siersbaek et al., 2010). In
chondrogenic differentiation, the Sex Determining Region Y-box 9 (SOX9) has been
identified as the essential transcription factor for chondrogenic differentiation (Akiyama
et al., 2004). By utilizing these key transcription factors that control cell fate, it is
possible to direct ESCs to differentiate into desired cell lineages.
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Biomedical Applications
Cells in the human body can be dysfunctional for a variety of reasons including
injury, genetics, disease, or aging. ESC’s pluripotency and ability to proliferate in vitro
through an extraordinary, nearly unlimited, self-renewal process make them excellent
candidates for cell sources in regenerative medicine. ESCs have the potential to treat
several diseases including cancers, Parkinson’s disease, spinal cord injuries, muscular
dystrophies, diabetes, and several others (Murnaghan, 2014). In cell culture, ESCs have
the ability to be grown indefinitely and to be manipulated genetically. Several
differentiation strategies for various cell lineages have already been established. Through
the manipulation of cell culture conditions and genetics, ESCs could be differentiated
into nearly any cell type to be used as treatments for various human diseases and
disorders (Wobus & Boheler, 2005).
Though hESCs have a lot of potential, differentiated hESCs exhibit several
complications. Currently, the differentiation methods for hESCs are low yielding and
create heterogeneous cell populations, meaning the cell populations are not uniform in
nature. If transplanted into the human body, the differentiated hESCs could be rejected by
the immune system, form tumors, or may not even function normally within the body.
Due to different histocompatibility complexes between the patient and donor,
immunorejection of ESCs could potentially occur (Drukker, 2004). Also as mentioned
earlier, the attenuated immune response of ESCs and their derivatives could cause
problems if exposed to pathogens during transplantation (Wang et al., 2013). It is vital
that these problems be resolved before hESCs can be used for various cell therapies
(Wobus & Boheler, 2005).
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Similarities and Differences between mESCs and hESCs
The majority of the current knowledge regarding the use of ESCs in cell-based
therapies comes from the study of animal models such as mESCs. While these models
can be helpful in determining the prospective use of ESCs in treatment of human
diseases, the use of hESCs would be much more beneficial. Although very similar,
differences do exist between mESCs and hESCs. One notable difference is that, unlike
mESCs, LIF is not sufficient to inhibit differentiation of hESCs. Some studies show the
application of extracellular matrix factors can be used to maintain the stem cell state of
hESCs. It has also been found that hESCs possess a longer than average population
doubling time in comparison to mESCs. Also, unlike mESCs, hESCs are able to
differentiate into trophoblast-like cells. Subtle differences in morphology, expression of
differentiation markers, cell cycle, cell-death regulating genes, and patterns of embryonic
antigen immunostaining were also found between mESCs and hESCs (Ginis et al., 2003).
Because of these differences, more research is necessary to fully understand the
application potential of hESCs in cell therapy.
Both mESCs and hESCs have been tested and analyzed in various animal models
for human diseases. The first therapeutic demonstration involved the transplantation of
mESC-derived cardiomyocytes into the ventricular myocardium of adult mice with
muscular dystrophy. Only 7 weeks after implantation, the cells showed several cell
markers inferring their differentiation into mature cardiomyocytes. The injected mice
were reported to have increased left ventricular function shortly after implantation. This
study verified the potential use of ESCs for cardiac therapy. Also, endothelial cells
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derived from hESCs were found to form microvessels after their implantation into mice
with an immunodeficiency disorder (Wobus & Boheler, 2005).
Although several studies suggest ESC-derived cells to be therapeutically useful, it is
still unknown whether these cells could function normally or exhibit long-term
functionality within the human body. Currently, there are no ESC therapies being tested
with human models. In addition to the technical and biological barriers mentioned for
mESCs, the social and ethical concerns as discussed below have delayed the medical
application of hESCs.
Ethical/Social Concerns and Alternatives for hESCs
Because of their embryonic origin, research dealing with ESCs has many ethical and
social concerns as well. It is true that blastocysts have the potential to develop a complete
and functional organism. The debate lies on the fine line of whether or not a 5-day-old
embryo is yet a human being. It is without doubt this debate is based on several
misconceptions. It is commonly misconceived that ESCs alone can form an entire
organism. A blastocyst is composed of about 100 cells with 30 to 34 of those cells being
the ICM. The remaining cells make up an outer layer known as the trophectoderm. This
layer is essential for the blastocyst to develop to maturity and for the production of the
placenta. In ESC research, the trophectoderm is extracted, and therefore ESCs are only
considered pluripotent. They are able to form nearly every tissue type of a human body,
but without the ability to form the extraembryonic tissue, a fully, functional organism can
never be created in vitro (Gilbert, 2004).
Also, a common belief is that ESCs are derived from aborted fetuses, which is not
true. In fact, there is no connection between ESCs and abortion. The current ESC lines
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were derived from blastocysts that were voluntarily donated from people participating in
In Vitro Fertilization. For In Vitro Fertilization, hundreds of eggs are fertilized in a petri
dish with the hopes that one will form a child. Five days after fertilization, a few of these
fertilized embryos are then transplanted into the uterus. If the transfer is successful, the
remaining embryos are then discarded. These embryos, that would normally be discarded,
are what we use today in ESC research if consent from the donor is provided (Gilbert,
2004).
Since the use of ESCs is sometimes referred to as “therapeutic cloning,” some people
mistake this for “reproductive cloning,” which is an entirely different mechanism. Human
cloning involves the transfer of DNA from the cells of one individual into an egg to form
an embryo. Reproductive cloning occurs when this very same embryo is then
transplanted into a mother’s uterus, and the developing baby, being genetically identical
to the original donor, is brought to full term. On the other hand, therapeutic cloning uses
only the blastocysts of these embryos, which then prevents the embryo from developing
beyond the blastocyst stage (Gilbert, 2004).
Due to the ethical and social concerns, countries have passed bioethical regulations
regarding ESC research (Wobus & Boheler, 2005). The National Institute of Health
provides support and funding for public stem cell research in the Unites States. The
institute articulates a clear distinction between “using” ESC and “deriving” ESC. They
will only fund research on ESCs already derived from discarded embryos formed through
In Vitro Fertilization with uncompensated consent of the donor. NIH will not under any
circumstances support research on new ESC lines.
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It is because of these issues that adult stem cells (ASCs) are now more commonly
used instead of hESCs for therapeutic use. For example, allogeneic ASCs in bone marrow
are transplanted as a treatment for Leukemia patients (Wobus & Boheler, 2005). Another
alternative to ESCs is the newly found induced pluripotent stem cell (iPSC). In 2006,
Takahashi and Yamanaka were able to successfully reprogram mouse somatic cells into
pluripotent cells using key transcription factors (Puri & Nagy, 2012) as previously
mentioned. Although iPSCs and hESCs exhibit several similarities including
morphology, proliferation, surface markers, gene expression, and in vitro differentiation,
genetic differences have been detected as well as other concerns. Further study of iPSCs
is critical before they can replace hESCs in clinical applications (Takahashi et al., 2007).
Adult Stem Cells
As development of the embryo in the womb continues, organ development becomes
required to form a complete and functional organism. It is at this point in development
when ASCs are first seen. These cells maintain their self-renewal properties, but are
restricted in their potency. After birth, ASCs reside in specific “stem cell niches”
throughout the body where their primary purpose is to maintain tissue homeostasis. They
do this by consistently replacing damaged cells after natural cell death (apoptosis) or
injury (Li & Xie, 2005). They can remain in a non-dividing state for several years, but
can then become activated in response to an injury or disease. ASCs exhibit multipotent
abilities, meaning they are only able to differentiate into a few specific cell types. They
can be found in several mature tissues within the human body including brain, skeletal
muscle, bone marrow, teeth, heart, and liver (NIH, 2014).
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Mesenchymal Stem Cells
Background
Research on ASCs began in the 1950s, when it was discovered that two types of
stem cells were present in bone marrow. The first type, hematopoietic stem cells, gives
rise to all the blood cells in the body including red blood cells, white blood cells, and
platelets. The second type of stem cell was found to be bone marrow stromal cells or
mesenchymal stem cells (MSC) that are capable of differentiating into a few cell types,
primarily bone cells (osteoblasts and osteocytes,) cartilage cells (chondrocytes,) and fat
cells (adipocytes) (NIH, 2014). In 1976, Fridenstein et al. were the first to describe MSCs
as clonal, plastic adherent cells that act as a source for fat, bone, and cartilage. Within the
bone marrow, MSCs primary function is to secrete extracellular matrix proteins, growth
factors, chemokines, and cytokines, thereby creating a tissue framework for the
hematopoietic cell system (Bobis, Jarocha and Majka, 2007).
Characteristics
In terms of their morphology, physiology, and expression of surface antigens,
MSCs create a heterogeneous cellular population. Their functionality largely differs
depending on their environmental factors. When MSCs are given sufficient room to
grow, they give rise to several fibroblastic colonies. Stem cells that are able to form these
colonies are referred to as colony unit forming stem cells. Findings regarding MSC
cultures are not entirely consistent. Past studies of MSCs derived from bone marrow have
shown homologous colonies expressing only a single cell type, while more recent studies
find heterogeneous colonies containing more than one cell type. The proliferation
potential of MSCs have also been found to differ from small and rapidly renewing to
large and slowly renewing. However, the most recent studies reveal MSC colonies
13

containing as many as three cell types: some being small and spindle shaped, some flat
and cuboidal, and the third type having a large nucleus to cytoplasm ratio, rapid selfrenewal properties, and great potential for multilineage differentiation (Bobis et al.,
2007).
A single specific cell marker that is mutually expressed throughout all MSCs has
yet to be identified. On the other hand, they do express a wide variety of adhesion
molecules, cytokines, growth factor receptors, and extracellular matrix proteins. MSCs
isolated from bone marrow express several markers in common including: CD44,
CD105, CD106, CD166, CD29, CD73, CD90, CD117, STRO-1, and Sca-1. These cells
also do not express cell markers specific to hematopoietic and endothelial cell lineages
such as CD11b, CD14, CD31, CD33, CD34, and CD45 (Bobis et al., 2007). It is more
specifically the lack of antigens CD14, CD34, and CD45 that enable scientists to
distinguish MSCs from hematopoietic precursor cells (Minguell, Erices and Conget,
2001).
MSCs have been found to greatly decrease with age. Newborns express the highest
amount of MSC with their levels decreasing to about half by the age of eighty (Bobis et
al., 2007). MSCs can be found in the previously described “stem cell niches” where they
remain inactive until they are confronted with injury, disease, or aging. This is when their
self-renewal capacity takes over, and they are able to efficiently replace damaged cells
(Minguell et al., 2001). Research is still determining why exactly MSCs remain in this
undifferentiated state within their niches. However, some studies indicate that a family of
signaling proteins known as Wnt proteins for maintaining MSC’s stem cell state (Bobis et
al., 2007).
14

Though MSCs reside primarily in bone marrow, recent studies suggest they can be
found in several other tissues as well. These tissues include trabecular bone, adipose
tissue, synovium, skeletal muscle, lung, deciduous teeth, and human umbilical cord
perivascular cells (Baksh, Song and Tuan, 2004). It has yet to be established whether or
not these MSCs act the same as bone marrow-derived MSCs. It has also been seen that
the differentiation potentials of MSCs vary depending on the isolation origin of the cells
(Barry and Murphy, 2004).
In Vitro Growth and Tri-Lineage Differentiation Potential
MSCs growth in-vitro is characterized by three distinct phases. The beginning
phase, known as the lag phase, lasts about three to four days, followed by an extensive
growth period called the log phase, and finally a stationary phase proceeds. In ideal
conditions, bone marrow-derived MSCs can be maintained in vitro for about twenty to
thirty population doublings, while still retaining the ability to differentiate (Bobis et al.,
2007). The cell cycle profile of MSCs include approximately 10% of the cells in the S,
G2, and M phases of the cell cycle and 90% in the G0 and G1 phases (Minguell et al.,
2001).
In order for MSCs to differentiate in vitro, a variety of factors including specific
differentiation factors, growth factors, basal nutrients, and cytokines are needed. Other
factors such as the cell density, mechanical forces, and spatial organization of cells also
control MSC’s differentiation potential. Studies suggest that the same factors can elicit
different differentiation results on various species. For example, when both human
derived MSCs (hMSC) and mouse derived MSCs (mMSC) are treated with
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dexametasone, hMSCs form osteogenic cell lineages while mMSCs form adipogenic
lineages (Bobis et al., 2007).
The exact mechanism through which MSCs differentiate has yet to be determined.
It is not clear whether there is a single multipotent MSC that gives rise to each cell
lineage or if MSCs make up a mixture of progenitor cells each committed to their own
distinct lineage (Bobis et al., 2007). To characterize MSCs, the cells must be able to
differentiate into three distinct tissue lineages: adipocytes, osteocytes, and chondrocytes,
but MSCs have also been found to exhibit a high degree of plasticity (Kimbrell et al.,
2014, Minguell et al., 2001). They have been found to also produce some nonmesenchymal cell types including neural cells, endothelial cells, and muscle cells. The
specific factors that promote these types of differentiation in vitro have yet to be
identified (Bobis et al., 2007). During tissue growth and repair in vivo, the body displays
an elevated demand for cell progenitors. MSCs, being uncommitted progenitors, have
been reported to travel to other tissues as a cell source. For example, this was exhibited
when MSCs in the bone marrow traveled to muscles to aid in skeletal muscle repair
(Minguell et al., 2001).
Biomedical Applications
MSCs make up only about .001% to .01% of the cells found in bone marrow. For
research purposes, it has been found easy to collect a mixture of cells from the adult bone
marrow that includes MSCs. However, being that MSCs make up such a small fraction of
bone marrow, it is extremely complicated to isolate a pure culture of MSCs, and scientists
have yet to find a successful way of doing this (Barry and Murphy, 2004). Though
several gaps exist in the research of MSCs, their easy isolation and culture, high ex vivo
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expansion potential, and multi-lineage differentiation potential give MSCs a promising
future in a wide range of clinical applications including regenerative medicine, gene
therapies, and tissue engineering (Minguell et al., 2001).
Several studies have already been conducted to demonstrate MSCs potential in
biomedical applications. It has been found that transplanted MSCs are stable when
engrafted into various tissues of animal models. Engrafted MSCs were even observed to
migrate to specific sites of injury including bone fractures, myocardial infarction, and
cerebral ischemia. MSCs also have excellent potential for gene therapies. In one study,
genetically modified MSCs were used successfully to transfer a therapeutic gene into a
mouse model. The MSCs were genetically modified through transduction with a viral
vector, and the transfer to the donor revealed 74% gene transfer efficiency. Genetically
altered MSCs have also been tested clinically in humans to treat hemophilia. MSCs were
modified to carry coagulation factors VII and IX and then transferred into hemophiliac
patients (Bobis et al., 2007).
MSCs have been used successfully for the treatment of bone defects in animal
models. Scaffolds containing recombinant bone morphogenetic proteins were used to
gather local MSCs to induce bone formation in rats. Furthermore, MSCs are currently
being used in several clinical trials to treat osteogenesis imperfecta, a genetic disorder
involving over 150 mutations that together cause many abnormalities especially in
collagen formation and bone structure. Some of the clinical trials involve engraftment of
purified populations of MSCs, MSC gene therapies, and even transplantation of MSCs in
utero in some severe cases of osteogenesis imperfecta (Bobis et al., 2007).
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MSCs have also been used for tissue engineering in the treatment of cartilage
lesions. Wakitani et al., (1994) used collagen sponges filled with MSCs to fill
mechanically induced cartilage lesions within white rabbits. Though active chondrocytes
and a cartilaginous matrix did indeed form, the new tissue and host tissue were found to
be discontinuous. Since then, MSCs stimulated with the growth factors BMP-2 and IGF-1
have been used successfully to repair knee joints (Bobis et al., 2007).
In addition to these uses, MSCs have also been found successful in several in vivo
tissue repairs including kidney, muscle, and lung repairs. Also, MSCs have been utilized
to promote angiogenesis and to treat chronic skin wounds. The biomedical use of MSCs
posses fewer limitations than ESCs. Unlike ESCs, MSCs have less ethical concerns and
are less probable to trigger tumor formation (Bobis et al., 2007).
ESC-derived MSCs
Harvesting MSCs from the body can be a difficult process that requires both a
perfect match donor and invasive procedures to extract the cells. Also, only a limited
number of MSCs can be isolated from a single donor, and these cells do not have the
capacity to proliferate for long periods of time. It is because of these reasons that
researchers sought out for a new source of MSCs other than adult tissues. Being that
ESCs have the capacity to produce unlimited specialized cells, several studies have
reported the differentiation of hESCs into cells that have very similar characteristics to
adult tissue-derived MSCs (Hematti, 2011). The potential of ESC-derived MSCs (ESCMSC) could provide an unlimited source of MSCs for various clinical applications. Due
to the inconsistencies regarding the definition for MSCs, the International Society for
Cellular Therapy recently put together a list of widely accepted criteria based on
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phenotypic and functional characteristics as well as specific culture properties. The
criteria include the tri-lineage differentiation into fat, cartilage, and bone tissues. MSCs
must be plastic-adherent when grown in standard culture condition. It also includes that
MSCs do not express the surface molecules CD34, CD45, CD14, CD11b, CD79α, CD19,
or HLA-DR, but include the surface makers CD73, CD90, and CD105 (Dominici, et al.,
2006). In 2005, Barberi, Willis, Socci and Studer. were able to characterize ESC-MSCs
using the above criteria after 40 days of coculture hESCs with murine bone marrow
stromal cells known as OP9 cells. The gene expression analysis of their ESC-MSCs also
showed 579 transcripts in common with human adult MSCs (Barberi et al., 2005). In
2011, Olivier and Bouhassira were able to derive MSCs from ESCs through the
“Raclure” method. This method produced ESC-MSCs without the coculture of OP9 cells
or any feeder layer (Olivier et al., 2011). Other methods of creating ESC-MSCs include
using embryoid body for formation, the plating of hESCs on MSC media, and inhibiting
TGFβ and MAPK signaling pathways (Kimbrel et al., 2014).
ESC-MSC’s potential in biomedical applications has been tested in a few studies
using disease models. ESC-MSCs were found to bring therapeutic benefits to mice with
trinitrobenzenesulfonic acid-induced colitis. Another study showed ESC-MSCs
enhancement of hematopoietic stem cell engraftments. Kimbrell et al., 2014 tested their
effects on mice with lupis nephritis and uveitis, two different autoimmune disorders. For
lupis nephritis, the ESC-MSCs helped preserve kidney function, thus leading to an
increased average lifespan of the mice. The cells were also found to decrease the severity
of uveitis in the mice models. They concluded that ESC-MSCs are an excellent
alternative to adult tissue-derived MSCs (Kimbrel et al., 2014).
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RATIONALE, HYPOTHESIS, AND OBJECTIVES
Due to their self-renewal properties and differentiation potential, ESCs are a
promising cell source for regenerative medicine. Though ESCs have great potential,
several challenges must be overcome before these cells can be used. Current methods of
ESC differentiation produce low-yielding, heterogeneous cell populations that are not
sufficient for biomedical applications. Differentiated ESCs have also been found to have
an attenuated immune response (Wang et al., 2013), giving us doubt to whether or not
they will function normally within the human body.
On the other hand, MSCs, a type of multipotent ASC found within bone marrow,
also have excellent characteristics for therapeutic applications. MSCs have already
advanced far in clinical applications due to their defined differentiation abilities and
immunoregulatory properties. However, these cells can only be derived from limited
sources and lack sufficient expansion capacity needed for use in biomedical applications
(Baksh, Song and Tuan, 2004).
The research question investigated in this project is to determine if mESC-derived
fibroblasts that were previously characterized (Wang et al., 2014) have characteristics in
common with MSCs. By characterizing these cells with properties defined for adult tissue
derived-MSCs, we will obtain novel information regarding their future use in therapeutic
applications. This will allow us to generate cells that possess advantages of both ESCs
and MSCs, thus creating a new and improved cell source for future biomedical
applications. Two graduate students, William D’Angelo and Chandan Gurung led this
research project under Dr. Guo’s direction. By participating in this research project, my
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objective is to gain a greater understanding of stem cell biology and to learn basic
research skills including laboratory techniques and procedures.

EXPERIMENTAL DESIGN AND METHODS
Experimental Design
Through retinoic acid (RA) induction, a cell line has been differentiated from
mESCs in Dr. Guo’s lab. Initially identified as fibroblasts (Wang et al., 2014), these cells
are now believed to share several characteristics with MSCs. The goal of this research
project is to characterize these cells as MSCs by examining cell morphology,
proliferation rate, cell cycle profile, and tri-lineage differentiation capacity (osteocytes,
adipocytes, and chondrocytes; NIH 2014). By characterizing these cells’ MSC properties,
we aim to show that the ESC-MSCs that are generated will be able to bypass several
complications that exist when using adult tissue-derived MSCs for biomedical
applications.
Cell Culture Techniques
Background
By definition, a cell culture is when cells are isolated from tissues or organs of an
organism during the cultivation process. The cells are then grown in an in vitro
environment such as a culture dish, containing a medium that provides the essential
nutrients for cell survival and growth such as glucose and amino acids. In 1907 Ross
Harrison was the first to create an animal cell culture, but it was not until the late 1940s
that the cell culture technique was developed enough to be readily used by scientists.
Several advances took place before this technique was perfected. First, the discovery and
use of antibiotics helped avoid contamination that plagued the early efforts of cell culture.
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Then enzymes such as trypsin were discovered to disassociate the cells from their culture
dish, enabling scientists to grow continuous cell lines. Lastly, culture media were
optimized to allow for sufficient cell growth in vitro. Continuing into the 1960s and even
today, commercialization of culture technology is expanding the use and efficiency of
cell cultures (Ryan, 2008).
The first step of creating a cell culture is producing the primary culture by
removing the cells from the desired tissue and placing them into the appropriate culture
environment. This can be done by one of two methods: explant culture or enzymatic
dissociation. In an explant culture, tissue pieces are isolated from the source and attached
to a culture dish. Culture medium is added to the dish. Cells are then able to move from
the tissue explant to the surface of the dish where they begin to divide. The second
method, enzymatic dissociation, is more commonly used. For this method, digestive
enzymes, such as trypsin, are used to dissolve the extracellular material holding the cells
together and form a suspension layer of cells that is then added to a culture dish with
medium. The cells are then able to grow and divide (Ryan, 2008).
To allow for continued growth and continuous cell lines, the cells of the primary
culture must be subcultured. When the cells from the primary culture have filled the
available space of the culture dish, trypsin is used to detach the cells from the culture
dish, and the cells are replated at a lower density. Extra cells that are not presently needed
can be treated with cryoprotective agents such as glycerol or dimethylsulfoxide, frozen,
and then usually stored in a liquid nitrogen tank below -130°C until they are needed.
Rather than establishing a new cell line through primary cultures, cell cultures can also be
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purchased from organizations such as the American Type Culture Collection (ATCC)
(Ryan. 2008).
Most cell lines derived from normal tissues contain cells that are anchoragedependent. This means they are only able to grow and divide when attached to an
appropriate substrate, a glass or plastic surface of a cell culture dish. Cells such as these
require specific attachment factors such as collagen or gelatin, which are used to coat cell
culture dishes and allow for better attachment. The culture medium is also very important
and must provide all necessary nutrients for cell growth, such as glucose and essential
amino acids. The medium should regulate the environment by optimizing pH and
osmolality through the use of buffer solutions. Growth factors and hormones are also
used within the medium to control the cells’ growth rate. These factors are usually
provided in the form of 5% to 20% animal sera, such as fetal bovine serum (FBS). Cells
are typically stored near 37°C in mammals or the body temperature of the organism in
which they were derived (Ryan, 2008).
ESC Culture
A D3 mESC cell line from ATCC (Toumadje et al., 2003) was cultured in dishes
coated with 0.1% gelatin and supplied with Dulbecco’s Modified Eagle Medium
(DMEM), supplemented with 15% FBS, 1000 U/mL LIF, non-essential amino acids, and
100 µg/mL streptomycin. The cells were then stored in a humidified incubator at 37°C in
5% CO 2 . Once the cells reached 100% confluence, meaning that the surface of the
culture dish was completely covered with a monolayer of cells, they were subcultured.
Trypsin, phosphate-buffered saline (PBS), and DMEM containing 15% FBS was heated
for 5 to 10 minutes at 37°C. The medium was removed from the culture dish by a suction
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pipette. PBS was added to the culture dish to wash the cells, and then also removed by
the suction pipette. Trypsin was added for 3-5 minutes to detach cells from the dish and
then an equal volume of DMEM with 15% FBS was added to deactivate the trypsin. The
cells were then placed in 1.5mL tubes and centrifuged at 1,100 rpm for 3.5 minutes. The
supernatant was removed, and the remaining cell pellet was resuspended in 1 mL of fresh
medium. The cells were replated on new dishes coated with gelatin at 50% to 60%
confluence and maintained as described above.
In Vitro Differentiation of mESCs
Retinoic Acid Induction
Retinoic acid (RA), a vitamin A derivative that regulates many developmental
processes during embryogenesis (Keller, 2005), was used to induce mESC
differentiation. Cell differentiation was begun by adding 1µM RA to mESCs in a gelatincoated culture dish. The cells were differentiated over a 10-day period with the cell
medium being refreshed three times over that period. Once the cells were differentiated,
they were trypsinized and replated in a culture dish without gelatin. The differentiated
cells were able to attach within 30 to 45 minutes. They express fibroblast markers and
show extensive similarities to 10T1/2 cells (Wang et al., 2014), therefore they are
tentatively defined as MSCs, and are referred to as D3-MSCs hereafter.
MSC Culture
D3-MSCs and C3H 10T1/2 cells (10T1/2, a line of mMSCs isolated from 14-17
day mouse embryos, ATCC) were cultured in DMEM + 10% FBS, 100 U/mL penicillin,
and 100 µg/mL of streptomycin. The cells were maintained at 37°C in a humidifying
incubator in a 5% CO 2 environment. The subculture procedure was identical to that of
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ESCs, except the culture dishes were not coated with 0.1% gelatin, as the cells have no
problem adhering to plastic. 10T1/2 cells have been used as a model for studying MSC
differentiation (Haas & Tuan, 2000) and are used in this project as a positive control. .
Toluidine Blue Staining
Principle of TB Staining
Toluidine blue (TB) was first discovered in 1856 when a chemist, William Perkin,
was attempting to synthesize quinine. Rather than his expected result, he produced a blue
substance with considerable staining properties. TB, the first synthetic organic chemical
dye, is a polychromatic dye that absorbs various colors depending on which tissues it
binds. It can selectively bind to acidic cellular components, having a very high affinity
for nucleic acids including both DNA and RNA. On the other hand, TB has less of an
affinity for proteins, thus minimizing the background staining of cells (Sridharan and
Shankar, 2012). Due to its relatively simple procedure, TB staining is commonly used as
a method to determine the number of cells and visualize morphology (Perry, 2014).
TB Staining Protocol
D3-ESCs, D3-MSCs, and 10T1/2 cells grown in a 48-well plate were fixed with
methanol for 5 to 10 minutes at room temperature. The methanol was then aspirated and
cell were air dried for 10 minutes. Cells were stained with 150 μl of TB for 30 minutes. A
bulb pipette was used to aspirate the stain from each well, and the wells were washed
with tap water 2-3 times. The stained cells were visualized using an Olympus CKX31
microscope.
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Cell Cycle Analysis by Flow Cytometry
Principle of Flow Cytometry
Flow cytometry is a technique used to analyze both the physical and chemical
properties of cells suspended in a thin stream of fluid and passed single file through a
laser. This technology is particularly useful in biological laboratories to study cellular
components as shown in Figure 3. Preferred components (i.e. DNA, specific proteins,
etc.) are labeled with fluorescent dyes that are then excited by a laser to emit light at
varying wavelengths, which is detected and digitized to enable software analysis. One of
the first practical uses of flow cytometry was cell cycle analysis through the quantitative
measurement of DNA content within cells (Ormerod, Tribukait and Giaretti, 1998).

Figure 3: The basic principle of flow cytometry. A phytoplankton cell flowing through
Flow Cytometry lasers with an exemplary scan (retrieved from
http://www.cytobuoy.com/faq/frequently-asked-questions/).

The cell cycle is split into distinct phases known as interphase and mitosis.
Interphase can be further broken down into three sub-phases: G1, S, and G2 as shown in
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Figure 4A. As discussed earlier, S phase is when the DNA synthesis takes place to
replicate the genome. The G1 and G2 phases, also known as the gap phases, involve cell
growth and preparation before mitosis, or M phase, can take place. The DNA within the
cell can be stained through a variety of DNA binding dyes including propidium iodide
(PI), 7-aminoactinomycin-D, as well as several others. These particular dyes are special
in that they are stoichiometric, meaning they are able to bind proportionately to the
amount of DNA in the cell. Cells in G2 or M phases (after DNA replication) will have
double the amount of DNA of cells in G1, and therefore fluoresce twice as brightly, while
cells in S phase will have an intermediate amount of amount of DNA and thus
fluorescence. This principle can be seen in Figure 4B (Ormerod, 1998).

Figure 4: The Phases of the Cell Cycle (A) and an example of a diploid DNA histogram
measured through Flow Cytometry (B) (Tabll and Ismail, 2011).

Cell Cycle Analysis Protocol
D3-ESCs and D3-MSCs were harvested at 30% to 80% confluence in 6-well
dishes. They were then washed in PBS, detached with 0.4 mL trypsin, and collected in a
1.5 mL tube. The wells were each washed with 0.4 mL of medium, which was then
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combined with the trypsinized cells. The cells were then centrifuged at 1200 rpm for 3
minutes. The supernatant was removed, and the pellet was broken up and resuspended in
200 μl of PBS+0.1% FBS. The cells were then fixed in 800 μl of 100% ethanol at 4°C for
30 minutes. Fixation is necessary to prevent deterioration of the cells and allow
permeabilization of the membrane to dyes or antibodies. After fixation, the cells were
centrifuged again at 1500 rpm for 5 minutes, and resuspended in 0.5 mL of PBS+0.1%
FBS to wash. After another centrifugation, cells were resuspended in 50 µL of PBS plus
1 µL of RNAse and incubated at room temperature for 10 minutes. The RNAse breaks
down all RNA within the cell, so only the DNA is measured allowing for fewer
distortions in the results. 100 µL of FACS buffer, containing both PBS and 2% FBS, and
10 µL of PI (1 mg/mL) were added to the cells. They were then incubated at 4°C for 30
minutes. The results were analyzed using a flow cytometer. Both the forward and side
scatter of the cells were measured to identify single cells.
Tri-lineage Differentiation Techniques
Principle of Spontaneous Differentiation
The principle of mESC differentiation is that, in the absence of LIF, mESCs begin
to spontaneously differentiate into various cell types. For effective cell type-specific
differentiation, specialized media that contain specific growth factors or cytokines are
commonly used. Although not very effective, it has been demonstrated that MSCs can
spontaneously differentiate in the absence of growth factors or specific environmental
conditions. Naruse et al., 2004, allowed MSCs obtained from fetal rat circulation to
differentiate in a normal medium without any additional factors. Both chondrocytes and
osteocytes were formed through spontaneous differentiation of the MSCs (Naruse et al.,
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2004). As an initial assessment, D3-MSCs were spontaneously differentiated for 4 weeks
to test their tri-lineage differentiation potential into osteocytes, adipocytes, and
chondrocytes.
Differentiation Protocol
D3-MSCs and 10T1/2 cells were plated in DMEM + 10% FBS and allowed to
grow for 4 weeks without subculturing. During this time, the medium was changed
regularly, approximately every 2 to 3 days. The cells were positively stained with
respective dyes for detection of cellular products. To compare levels and intensity of
staining, cells were stained after 3 days to use as an undifferentiated control and again
after 4 weeks of growth.
Osteocyte Staining
Osteocytes, or bone cells, have the capacity to undergo mineralization, which is
when cells produce extracellular calcium deposits when grown in vitro. The formation of
calcium deposits indicates successful osteogenic differentiation. Alizarin Red can be used
to stain calcium deposits a bright orange-red color to test for successful bone formation
(Gough, Jones and Hench, 2004). Prior to staining, the cells were fixed in methanol, and
2% Alizarin Red S was filtered before use. The cells were washed twice in PBS, then
stained with 2% Alizarin Red S for 5 minutes. They were then washed 3 times in distilled
water and visualized with a microscope.
Adipocyte Staining
Oil Red O is a stain that can be used to detect the extent of adipocyte
differentiation. It does so by staining the intracytoplasmic lipids within the cells
(Ramirez-Zacarias, Castro-Munozledo and Kuri-Harcuch, 1992). Both D3-MSCs and
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10T1/2 cells were stained to confirm adipocyte formation. Prior to staining, the cells were
fixed in methanol, and 0.5% Oil Red O was diluted in a 3:2 ratio (stain: distilled water).
The stain was mixed, left to stand for 10 minutes, and then filtered before use. The cells
were washed twice in PBS stained with 0.5% Oil Red O for 5 minutes, washed 3 times in
PBS, and visualized with a microscope.
Chondrocyte Staining
Safranin O is a cationic dye that is used to quantify the amount of proteoglycans
present in cartilage. When chondrogenic differentiation occurs, extracellular matrix
proteins including type II collagen and the proteoglycan aggrecan begin to form. The
higher the intensity of the safranin staining, the higher the proteoglycan content
(Camplejohn and Allard, 1988). To test for successful chondrocyte formation, both D3MSCs and 10T1/2 cells were stained with Safranin O. Prior to staining, the cells were
fixed with methanol and washed three times with PBS. The cells were stained with 0.1%
Safranin O for 5 minutes, washed with distilled water, and visualized with a microscope.
RNA Extraction and RT-qPCR
Principle of PCR-based Gene Expression Analysis
Real time quantitative polymerase chain reaction (RT-qPCR) is a procedure that
measures amplified DNA through the use of fluorescent molecules. DNA binding
chemicals such as SYBR green bind to double stranded DNA and become fluorescent. As
DNA is amplified, double stranded DNA begins to increase, and in turn so does the
fluorescence. This allows for the measure of DNA amplification. RT-qPCR can be split
into four phases: the linear ground phase, early exponential phase, log-linear phase, and
plateau phase as shown in Figure 5. During the linear ground phase, there is not enough
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DNA for an increase in fluorescence to be detected, but the baseline fluorescence can be
calculated. In the early exponential phase, the fluorescence has reached a threshold where
an increase can be detected. The cycle in which this occurs is called C t , indicated by the
arrow in Figure 5. The C t value is used as a measure of the original amount of
complementary DNA (cDNA). In the log-linear phase, DNA reaches optimal
amplification and is approximately doubled during each cycle. Finally, the plateau phase
is when the reaction components, such as nucleotides, become scarce, DNA amplification
slows down, and the fluorescence intensity is no longer needed for calculations. The
relative expression of genes of interest can be determined by comparing C t values to
housekeeping genes, or genes that are stably expressed across all samples and treatments
being tested. Some common housekeeping genes are β-actin and GADPH (Wong &
Medrano, 2005). For analysis, one of the most common methods to use is the
comparative C t method. This method uses a formula to compare the relative expressions
of the gene of interest and housekeeping gene. The formula is as follows (Pfaffl, 2001):

Expression in experimental group = 2(Ct ref-Ct gene of interest) experimental
Expression in control group
2 (Ct ref-Ct gene of interest) control
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Figure 5: Phases of RT-qPCR. The arrow indicates the C t value (modified from Wong &
Medrano, 2005).

RNA Extraction
Sigma Tri-reagent was used to isolate RNA from the cells. 0.6mL was added to
each well in the culture dish (6-well plate). The cells were then transferred to 1.5mL
microfuge tubes. 0.2mL of chloroform per mL of Tri-reagent was then added to each
microfuge tube. The cells were vortexed for 15 seconds and then incubated at room
temperature for 10 minutes. After incubation, the cells were centrifuged at 10,000 rpm for
10 minutes at 4°C, and three different phases were formed: aqueous phase, interphase,
and organic phase. The aqueous phase containing the RNA was transferred to another
tube. Due to the amphipathic characteristics of proteins, they were attracted to both the
organic and aqueous phases and were found in the interphase or flocculent. Due to both
the acidic conditions and the presence of phenol, DNA ended up in the organic phase and
interphase. Furthermore, the phosphate groups of DNA are neutralized by H+, causing it
to be nonpolar, thus making DNA be attracted to both the organic phase and interphase.
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Next, 0.5 mL of 100% isopropanol per mL of Tri-reagent was added to the aqueous phase
containing the RNA. The sample was then incubated at room temperature for 10 minutes
before centrifugation at 12,000 rpm for 15 minutes at 4°C. After centrifugation, a white
pellet of RNA had precipitated. The liquid was removed from the tube, leaving only the
RNA pellet, and 700 μl of 75% ethanol were added to wash the pellet. The sample was
vortexed and put in the freezer at -20°C for at least 1 hour to allow for the RNA to
precipitate. The sample was then centrifuged at 10,000 rpm at 4°C for 10 minutes. The
ethanol was removed, and the pellet was dried on ice for 5 minutes. The pellet was
dissolved in 20µL of Diethylpyrocarbonate (DEPC) water. Using a spectrophotometer,
both the concentration and integrity were determined. The sample was stored at -70°C for
later use.
Reverse Transcription Protocol
In order to generate cDNA for use in RT-PCR, reverse transcription was
performed using M-MLV reverse transcriptase. For each sample, 1 μg RNA was diluted
to a 11.5 µL total volume with sterile water. Then 1 µL of deoxyribonucleotide mix and 2
µL of oligo(dT) primer was added. Samples were then vortexed, incubated at 70°C for 5
minutes, and placed on ice. Then 4µL of 5X buffer and 1 µL reverse transcriptase were
added and samples were placed in a thermal cycler and incubated at 42°C for 1 hour, then
95°C for 10 minutes to inactivate the enzyme. Finally 200µL of sterile water were added
and samples were stored at -20°C until later use.
Semi-quantitative PCR Protocol
A 20 µL solution was made for each sample by combining 10 µL of 2X SYBR
mix, 3 µL of DEPC water, 5 µL of cDNA, and 2 µL of primers specific to the gene of
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interest. Samples were run for 35 cycles (10 min at 95°C initial denaturation, then 35
cycles of 95°C for 15s for denaturation, and 60°C for 1 min for annealing/elongation) on
a Stratagene MX3000P real-time PCR thermal cycler using MxPro software, and data
were analyzed through the use of the comparative C t method (Pfaffl, 2001). The
housekeeping gene used for comparison was β-actin. Primer sequences were as follows:
Gene

Forward Primer Sequence

Reverse Primer Sequence

C/EBPα

5’- CAAGAACAGCAACGAGTACCG-3'

5'-GTCACTGGTCAACTCCAGCAC-3'

PPARγ

5'-GGAAGACCACTCGCATTCCTT-3'

R: 5'-GTAATCAGCAACCATTGGGTCA-3'

RUNX2

F: 5'-GCCCAGGCGTATTTCAGA-3'

R: 5'-TGCCTGGCTCTTCTTACTGAG-3'

OCN

5'-CTGACCTCACAGATGCCAAG-3'

R: 5'-GTAGCGCCGGAGTCTGTT-3'

SOX9

F: 5'-AGTACCCGCATCTGCACAAC-3'

R: 5'-ACGAAGGGTCTCTTCTCGCT-3'

COL2A1

F: 5'-GGGTCACAGAGGTTACCCAG-3'

R: 5'-ACCAGGGGAACCACTCTCAC-3'

RESULTS
Comparison of mESCs, D3-MSCs, and 10T1/2 Cell Morphology
To begin the characterization process, the morphology of D3-ESCs, 10T1/2 cells,
and D3-MSCs was compared after the cells were stained with TB. As shown in Figure 6,
D3-ESCs exhibit typical ESC morphology of undifferentiated cells growing together in
clustered colonies. They also possess a large nucleus to cytoplasm ratio. According to
Wobus and Boheler (2005), ESCs typically grow in tight, rounded, multilayered clusters.
On the other hand, the D3-MSCs completely lost the morphology of ESCs. They instead
expressed flattened, elongated spindle-shaped cells very similar to 10T1/2 cells. Both
populations of cells were similar in morphology and grew in a uniform monolayer, very
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different from the colonies of D3-ESCs. According to Baksh, Song and Tuan (2004), the
gold standard assay used to identify MSCs is to identify adherent, spindle-shaped cells.

A

B

C

Based on the results in Figure 6, D3-MSCs were confirmed to possess MSC morphology.

Figure 6: Morphological comparison of D3-ESCs at 400x (A), D3-MSCs at 400x (B),
and 10T1/2 cells at 200x (C). The images were taken with a digital camera under a phase
contrast microscope.

Cell Proliferation and Cell Cycle Profile
The cell cycle profiles of D3-ESCs and D3-MSCs were analyzed by flow
cytometry. This profile measures both the number of cells at each phase of the cell cycle
(Y-axis) and the amount of DNA at that particular phase (determined by fluorescence
intensity, X-axis). The first peak in the profile represents cells found in the G1 phase,
while the second peak corresponds to cells found in the G2 and M phases of the cell
cycle, and cells in between these peaks are in S phase, as labeled in Figure 7. For D3ESCs, the cell cycle profile included a high percentage of cells in the S, M, and G2
phases of the cell cycle, meaning that a lot of cells were actively dividing and rapid cell
division was occurring. mESCs are characterized by their high proliferation rate (Wobus
and Boheler, 2005), and their cell profiles typically show about 60% of cells in the S
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phase. On the other hand, the cell cycle profile of D3-MSCs show a reduced cell
population at the S, G2, and M phases of the cell cycle, indicating MSC’s slower
proliferation rate when compared with D3-ESCs. MSCs are characterized by having only
10% of the cells in the S, G2, and M phases of the cell cycle and 90% in the G0 and G1
phases, indicating that only a small fraction of MSCs are actively engaged in proliferation
(Minguell et al., 2001). Based on this information, the cell cycle profile of D3-MSCs was
more similar to the cell cycle of MSCs than ESCs.

Figure 7: Cell Cycle Profiles of D3-ESCs (A) and D3-MSCs (B) determined by flow
cytometry.

Osteogenic Differentiation
To confirm that osteogenic differentiation had occurred after 10T1/2 cells and
D3-MSCs were given 4 weeks to spontaneously differentiate, the cells were stained with
Alizarin Red as previously described. They were stained both 3 days into differentiation
and again after 4 weeks of differentiation. The results in Figure 8 show strong staining at
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the 4 week timepoint compared with undifferentiated controls in both cell types, thus
indicating that mineralization had occurred and osteocytes had been formed (Gough et
al., 2004).

Figure 8: Osteogenic Staining. 10T1/2 cells (A) and D3-MSCs (B) 3 days into
spontaneous differentiation after staining with Alizarin Red and 10T1/2 cells (C) and D3MSCs (D) four weeks into spontaneous differentiation after staining with Alizarin Red.
All images are taken at 400x magnification under a phase contrast microscope.
To further confirm that osteogenic differentiation had occurred, the expression of
specific transcription factors and structural proteins in D3-MSCs was measured using
RT-qPCR. The genes that were measured included the transcription factor, RUNX2, and
the structural protein osteocalcin (OCN). RUNX2 has been identified as a primary
transcription factor needed for osteocyte differentiation, bone matrix gene expression,
and bone mineralization (Nakahara et al., 2010). OCN is used as a marker to identify late
stages of osteogenic differentiation (Granéli et al., 2014). As shown in Figure 9, OCN
expression increased over the 4 week differentiation period, suggesting that osteogenic
differentiation had occurred.
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Figure 9: Expression of Runx2 and OCN in undifferentiated D3-MSCs (con) and 2
weeks and 4 weeks into spontaneous differentiation determined by RT-qPCR.

Adipogenic Differentiation
After 10T1/2 cells and D3-MSCs were spontaneously differentiated, lipid droplets
became visible in the cytoplasm. Adipocytes in both populations of cells can be seen in
Figure 10 (A and B) after spontaneously differentiating for 4 weeks. To confirm that
adipogenic differentiation had occurred, D3-MSCs were positively stained with Oil Red
O (Figure 10 C). This stain is used for the detection of intracytoplasmic lipids present
within cells (Ramirez-Zacarias et al., 1992).

Figure 10: Adipogenic differentiation. 10T1/2 cells (A) at 400x magnification and D3MSCs (B) at 560x magnification observed 4 weeks into spontaneous differentiation, but
prior to staining. D3-MSCs (C) positively stained with Oil Red 4 weeks into spontaneous
differentiation (400x). All images are taken under a phase contrast microscope.
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To further confirm adipogenic differentiation, RT-qPCR was used to measure the
expression of transcription factors essential to adipogenic differentiation, including
PPARγ and C/EBPα. Both families of transcription factors have been found to play
important roles during adipocyte differentiation. Several studies have confirmed PPARγ
to be the key transcription factor in adipocyte differentiation in both in vitro and in vivo
environments. C/EBPα is expressed during late stages of differentiation and is also one
of the key regulators in adipocyte differentiation (Siersbaek et al., 2010). Expression of
both transcription factors was somewhat increased in D3-MSCs at both 2 weeks and 4
weeks after spontaneously differentiating as shown in Figure 11, indicating adipogenic
differentiation.

Figure 11: Expression of PPARγ and C/EBPα in undifferentiated D3-MSCs (con) and
after 2 weeks and 4 weeks of spontaneous differentiation determined by RT-qPCR.

Chondrogenic Differentiation
As previously described, D3-MSCs and 10T1/2 cells were stained with Safranin
O during their spontaneous differentiation to detect whether or not chondrogenic
differentiation had occurred. The cells that were stained after only 3 days had not yet
differentiated and were not able to retain the Safranin when stained. On the other hand,
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the cells that had been given 4 weeks to spontaneously differentiate stained an intense red
color indicating that the cells contained high proteoglycan content and chondrocytes were
formed (Camplejohn and Allard, 1988).

Figure 12: Chondrogenic differentiation. Undifferentiated 10T1/2 cells (A) and D3MSCs (B) and cells after 4 weeks of differentiation (C and D) stained with Safranin O.
All images are shown at 400x magnification under a phase contrast microscope.

The expression of chondrogenic differentiation markers in differentiated D3MSCs was measured using RT-qPCR as previously described. These markers included
the transcription factor SOX9 and COL2A1, the protein-coding gene that produces type
II collagen. SOX9 is a transcription factor that is present in all differentiated
chondrocytes and plays an essential role in the early stages of chondrogenic
differentiation. This transcription factor is also needed to activate the COL2A1 gene to
begin type II collagen formation. All mature chondrocytes have been found to express
type II collagen (Akiyama et al., 2004). As shown in Figure 13, the expression of SOX9
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was expressed highly in D3-MSCs both 2 and 4 weeks into spontaneous differentiation,
indicating that beginning stages of chondrocyte formation had occurred. COL2A1, on the
other hand, was not expressed in D3-MSCs indicating a lack of mature chondrocytes in
the sample.

Figure 13: Expression of SOX9 and COL2A1 in undifferentiated D3-MSCs (con) and
the same cells after 2 4 weeks of spontaneous differentiation determined by RT-qPCR.

DISCUSSION
This goal of this study was to determine whether mESC-derived fibroblasts, that
we have previously characterized, have properties of MSCs. By participating in this
research project, my objective was to gain a greater understanding of stem cell biology
and to become familiar with basic research skills and laboratory procedures.
Based on the morphology comparison in Figure 6, D3-MSCs are clearly more
similar in shape to 10T1/2 cells than to D3-ESCs. Both D3-MSCs and 10T1/2 cells
possessed a flattened, elongated, spindle-shaped morphology, therefore displaying typical
MSC morphology (Baksh, Song and Tuan, 2004.) The results in Figure 7 demonstrated
that the cell cycle profile of D3-MSCs was more similar to that of MSCs than ESCs. This
was due to the reduced cell population found in the S, G2, and M phases of the cell cycle,
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indicating a lower proliferation rate than that of D3-ESCs. When D3-MSCs were
spontaneously differentiated for 4 weeks, they were able to form osteocytes, adipocytes,
and chondrocytes although these cells are not yet fully matured as indicated by the lack
of COL2A1 in chondrogenic differentiation, therefore confirming the tri-lineage
differentiation potential characteristic to MSCs. By staining the cells with Alizarin Red,
Oil Red, and Safranin and also measuring the expression of differentiation markers
through RT-qPCR, we were able to further confirm the identity of the differentiated cells,
and thus the tri-lineage differentiation potential. In conclusion, based on the results from
morphology, cell cycle profile, and tri-lineage differentiation potential, this research
provide strong evidence that D3-MSCs do possess several characteristics in common
with MSCs.
Though this study was able to provide several similarities between D3-MSCs and
MSCs, it only focuses on some basic aspects of MSC characterization, thus more
research is needed to further confirm their true identity, such as tri-lineage differentiation
under defined conditions with specific inducers for each of the three cell types. Some
other aspects of these cells that should be analyzed include surface antigens and
immunomodulatory properties. There is a specific set of surface antigens that are
expressed in MSCs. Moreover, MSCs are characterized by having both the presence and
absence of specific cell markers. Analysis of marker expression could be performed in
D3-MSCs through either flow cytometry or immunocytochemistry. MSCs have been
found to exhibit modulatory effects on the immune system. This characteristic brings a
lot of interest to their use in future biomedical applications. The innate immunity of D3-
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MSCs should be researched to see if they have similar responses to MSCs (Bio-Techne,
2014).
This study is significant, because the ability to generate MSCs from ESCs
bypasses many of the complications experienced when using adult tissue derived-MSCs.
Adult tissue-derived MSCs, such as bone-marrow-derived MSCs, have a lot of potential
for biomedical applications, but the major problem interfering with their use is their
limited numbers due to limited tissues of derivation (Baksh, Song and Tuan, 2004). The
ability to create MSCs from ESCs could be able to bypass this difficulty, providing an
almost unlimited source of MSCs for biomedical applications. In conclusion, the
characterization of D3-MSCs and the ability to generate MSCs from ESCs is a significant
stride forward towards the use of ESCs in regenerative medicine.
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